Seroatlas · Human Serome Atlas

RPRD1A

Regulation of nuclear pre-mRNA domain-containing protein 1A

Also known as: FLJ10656, HsT3101, P15RS, RPR1A_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q96P16
Gene: RPRD1A
Ensembl: ENSG00000141425
Chromosome: 18
Canonical length: 312 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm,Golgi apparatus

OverviewNCBI Gene

This gene encodes a cell-cycle and transcription regulatory protein. The encoded protein interacts with the cell cycle inhibitor cyclin-dependent kinase 4 inhibitor B and may function as a negative regulator of G(1)/S phase progression. This protein also forms homo- and hetrodimers with the protein, regulation of nuclear pre-mRNA domain-containing protein 1B, to form a scaffold that interacts with the C-terminal domain of RNA polymerase II subunit B1 and regulates several aspects of transcription. Alternate splicing results in multiple transcript variants. A pseudogene of this gene is found on chromosome 16. [provided by RefSeq, Dec 2014]

Canonical amino-acid sequenceUniProt

312 residues, UniProt reviewed canonical sequence.

>Q96P16|RPRD1A
     1  MSAFSEAALE KKLSELSNSQ QSVQTLSLWL IHHRKHSRPI VTVWERELRK AKPNRKLTFL
    61  YLANDVIQNS KRKGPEFTKD FAPVIVEAFK HVSSETDESC KKHLGRVLSI WEERSVYEND
   121  VLEQLKQALY GDKKPRKRTY EQIKVDENEN CSSLGSPSEP PQTLDLVRAL QDLENAASGD
   181  AAVHQRIASL PVEVQEVSLL DKITDKESGE RLSKMVEDAC MLLADYNGRL AAEIDDRKQL
   241  TRMLADFLRC QKEALAEKEH KLEEYKRKLA RVSLVRKELR SRIQSLPDLS RLPNVTGSHM
   301  HLPFAGDIYS ED

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against RPRD1A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.4
Highest tissue expression: 109 nTPM

Expression across tissuesHPA

Tissue

epididymis: 109 nTPM
skeletal muscle: 51 nTPM
cerebral cortex: 44 nTPM
tongue: 43 nTPM
amygdala: 42 nTPM
spinal cord: 42 nTPM

Single-cell type

late spermatids: 555 nCPM
epididymal principal cells: 434 nCPM
early spermatids: 308 nCPM
sertoli cells: 238 nCPM
neutrophils: 190 nCPM
somatotrophs: 171 nCPM

Immune cell

myeloid DC: 7.8 nTPM
NK-cell: 7 nTPM
intermediate monocyte: 6.3 nTPM
naive B-cell: 5.4 nTPM
plasmacytoid DC: 5.4 nTPM
memory B-cell: 5 nTPM

Brain region

cerebral cortex: 63 nTPM
basal ganglia: 61 nTPM
white matter: 60 nTPM
hypothalamus: 60 nTPM
thalamus: 60 nTPM
spinal cord: 57 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.58
gnomAD pLI: 0.22
gnomAD missense Z: 1.94
DepMap mean gene effect: 0
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

CID domain
ENTH/VHS
RPRD1A/B, C-terminal domain
CID domain
Cell-cycle alteration and expression-elevated protein in tumour
RPRD1A, CID domain

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of RPRD1A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads RPRD1A as an antibody target. Whether an autoantibody or antibody against RPRD1A could matter depends on whether native RPRD1A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

RPRD1A is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label RPRD1A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...